(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
01 November 2018 (01.11.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/200918 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/US2018/029728

(22) International Filing Date:
27 April 2018 (27.04.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/492,056 28 April 2017 (28.04.2017) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1790 (US).

(72) Inventors: **BRYCH, Stephen, Robert**; 2488 Gillingham Circle, Thousand Oaks, CA 91362 (US). **WONG, Lyanne, M.**; 28861 Silversmith Drive, Valencia, CA 91354 (US). **FALLON, Jaymille**; 28915 Lodgewood Street, Newbury Park, CA 91320 (US). **GOSS, Monica, Michelle**; 3050 Lodgewood Street, Newbury Park, CA 91320 (US). **GU, Jian, Hua**; 1525 Silver Shadow Drive, Thousand Oaks, CA 91320 (US). **GHATTYVENKATAKRISHNA, Pavan, K.**; 1690 Springhaven Ave., Newbury Park, CA 91320 (US).

(74) Agent: **HONG, Julie, J.**; Marshall, Gerstein & Borun LLP, 233s. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

(54) Title: FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME



FIGURE 1

(57) Abstract: Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.

WO 2018/200918 A1

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*